Vaxcyte to Present Phase 1/2 Results of VAX-31 Pneumococcal Vaccine in Adults 50+

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, is set to hold a webcast and conference call on September 3, 2024, at 8:00 a.m. Eastern Time. During the event, the company will present topline results from its Phase 1/2 study on the safety, tolerability, and immunogenicity of VAX-31. VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) in healthy adults aged 50 and older.

To join the conference call, participants can dial 800-225-9448 within the U.S. or 203-518-9708 internationally, using conference ID PCVX0903. Additionally, a live webcast will be accessible on the investor relations page of Vaxcyte's website, with the event archived online for 30 days post-webcast.

Vaxcyte is dedicated to developing high-fidelity vaccines to protect against bacterial diseases. Their lead candidate, VAX-24, is a 24-valent, broad-spectrum PCV that is Phase 3-ready and aims to prevent IPD. VAX-31, Vaxcyte's next-generation 31-valent PCV, is currently the broadest-spectrum PCV candidate in clinical trials. Both VAX-24 and VAX-31 are designed to enhance the existing standard-of-care PCVs for both children and adults by targeting serotypes responsible for significant IPD cases, known for high fatality rates, antibiotic resistance, and meningitis, while also maintaining coverage of previously circulating strains.

Vaxcyte employs modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., to re-engineer the production of highly complex vaccines. This method aims to accelerate the creation and delivery of high-fidelity vaccines with improved immunological benefits, compared to conventional cell-based approaches.

The company's pipeline includes VAX-A1, a prophylactic vaccine candidate to prevent Group A Streptococcus infections; VAX-PG, a therapeutic vaccine aimed at slowing or stopping the progression of periodontal disease; and VAX-GI, a vaccine candidate intended to prevent Shigella. Vaxcyte's mission is to eliminate or treat invasive bacterial infections, which can have serious and costly health repercussions if left untreated.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!